Repare Therapeutics Announces March 2021 Virtual Investor Conference Participation
Repare Therapeutics (Nasdaq: RPTX), a clinical-stage precision oncology company, announced participation in three virtual investor conferences in March 2021. Key events include the Cowen 41st Annual Healthcare Conference on March 2, focusing on ovarian cancer, and the H.C. Wainwright Global Life Sciences Conference on March 9-10. Additionally, Repare will attend the Morgan Stanley Virtual Healthcare Corporate Access Day on March 16. The H.C. Wainwright presentation will be available for replay on the Company’s website for 30 days, showcasing its innovative cancer therapies and pipeline development.
- Participation in three significant virtual investor conferences, enhancing visibility.
- Showcasing innovative approaches and pipeline, particularly in precision oncology.
- None.
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced that members of its senior management team are scheduled to participate in three virtual investor conferences in March. Details are as follows:
Cowen 41st Annual Health Care Conference
Panel Discussion Title: Ovarian Cancer
Date: Tuesday, March 2, 2021
Time: 12:50 p.m. Eastern Time
H.C. Wainwright Annual Global Life Sciences Conference
Date: Tuesday, March 9 – Wednesday, March 10, 2021
Morgan Stanley Virtual Healthcare Corporate Access Day
Date: Tuesday, March 16, 2021
The prerecorded H.C. Wainwright presentation will be available on Tuesday, March 9, 2021, at 7:00 a.m. Eastern Time in the Investor section of the Company’s website at https://ir.reparerx.com/news-and-events/events. A replay of the webcast will be archived on the Company’s website for 30 days.
About Repare Therapeutics, Inc.
Repare Therapeutics is a leading clinical-state precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx® platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company’s pipeline includes its lead product candidate RP-3500, a potential leading ATR inhibitor currently in Phase 1/2 clinical development, as well as RP-6306, a CCNE1-SL inhibitor and a Polθ inhibitor program. For more information, please visit reparerx.com.
SNIPRx® is a registered trademark of Repare Therapeutics Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210223005218/en/
FAQ
What is Repare Therapeutics focused on?
What are the dates of the upcoming investor conferences for Repare Therapeutics?
Where can I find the H.C. Wainwright presentation by Repare Therapeutics?
What is the lead product candidate of Repare Therapeutics?
